Ascentage Pharma Group International (HKSE:06855) Other Stockholders Equity : HK$-540.2 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Other Stockholders Equity?

Ascentage Pharma Group International's Other Stockholders Equity for the quarter that ended in Jun. 2024 was HK$-540.2 Mil.

Ascentage Pharma Group International's quarterly Other Stockholders Equity declined from Jun. 2023 (HK$-524.1 Mil) to Dec. 2023 (HK$-551.8 Mil) but then increased from Dec. 2023 (HK$-551.8 Mil) to Jun. 2024 (HK$-540.2 Mil).

Ascentage Pharma Group International's annual Other Stockholders Equity increased from Dec. 2021 (HK$-674.6 Mil) to Dec. 2022 (HK$-579.0 Mil) and increased from Dec. 2022 (HK$-579.0 Mil) to Dec. 2023 (HK$-551.8 Mil).

Ascentage Pharma Group International Other Stockholders Equity Historical Data

The historical data trend for Ascentage Pharma Group International's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Other Stockholders Equity Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

990.72

-604.35

-674.62

-579.03

-551.77

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Stockholders Equity	Get a 7-Day Free Trial										1,027.63	-579.03	-524.07	-551.77	-540.20

Ascentage Pharma Group International Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Ascentage Pharma Group International Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.

Executives

Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc	2301 Trustee
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Tian Yuan	2201 Interest of corporation controlled by you
Zhao Li	2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines